AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03231332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome Diversity detection
Description: detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
Study NCT00934414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: 30U
Study NCT00890799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shanghai pmVSD occluder
Description: Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
Study NCT00890799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patient in this group received open surgical repair of pmVSD.
Study NCT01086384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444
Description: Combination inhaled corticosteroid and long-acting beta2-agonist
Study NCT01086384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Inhaled corticosteroid
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 1
Description: Receive at Months 0 and 1
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 0 and 1
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Month 0
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 3 and 4
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted GSK investigational HIV vaccine formulation 2
Description: Receive at Months 0, 1, and 4
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Month 4
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35 investigational HIV vaccine
Description: Receive at Months 0, 1, and 4
Study NCT01264445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: (Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Study NCT02834936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Study NCT01037062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, P.O. 0.5, 1 mg, once daily
Study NCT02592499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM III
Study NCT02592499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMM, optimal medical management
Description: Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
Study NCT04400344 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03644524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Regular hot tub use
Study NCT00519064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza vaccine
Study NCT04626271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACR | U.S. Urine Analysis Test System
Description: Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health.
Study NCT04626271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URiSCAN Optima Urine Analyzer
Description: Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer.
Study NCT01658904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT00427999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT03807453 — intervention group
Intervention type: OTHER
Intervention: Microbiota
Description: The scalp microbiota
Study NCT02637856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
Study NCT02637856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Study NCT04307641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Page Information Sheet
Description: 2 page information sheet about medication abortion
Study NCT02216578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Oral
Study NCT00904683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks
Study NCT00904683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously (IV) every 4 weeks for 80 weeks
Study NCT02238964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
Study NCT02238964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Closure
Description: The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
Study NCT03696641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glazed lithium disilicate crowns
Description: glazing of IPS e.max crowns
Study NCT03696641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glazed lithium disilicate crowns
Description: glazing of IPS e.max crowns
Study NCT03696641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: polished lithium disilicate crowns
Description: polishing of IPS e.max crowns
Study NCT03696641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished lithium disilicate crowns
Description: polishing of IPS e.max crowns
Study NCT00427999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfane
Study NCT00427999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Study NCT00427999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Study NCT00427999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT04402359 — intervention group
Intervention type: DRUG
Intervention: meropenem
Description: meropenem one gram slowly IV infusion every 8 hours for 14 days
Study NCT04402359 — intervention group
Intervention type: DRUG
Intervention: ceftazidime 2 grams and avibactam 500
Description: received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
Study NCT04402359 — intervention group
Intervention type: DEVICE
Intervention: ventilator
Description: all patients selected to be ventilated for 14 days
Study NCT04757324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding education
Study NCT01689233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 200 mg/day
Description: TRx0237 100 mg tablets will be administered twice daily.
Study NCT01689233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study NCT01004718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F18
Description: Undergo FDG PET/CT scans
Study NCT01004718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT scans
Study NCT03585283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Group
Description: Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
Study NCT03585283 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
Study NCT01627470 — intervention group
Intervention type: DEVICE
Intervention: CNAP-Monitor
Description: Continuous non-invasive arterial blood pressure recording
Study NCT01004718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Undergo FDG PET/CT scans
Study NCT00516802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study NCT00516802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: intravenous injection over at least 20 minutes
Study NCT00677859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem®
Description: Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
Study NCT00677859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem®
Description: Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
Study NCT02327013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine 10 mg tablet
Description: Oral tablets, once daily
Study NCT02327013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine 20 mg tablet
Description: Oral tablets, once daily
Study NCT02327013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral tablets, once daily
Study NCT00492232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and zolpidem
Description: Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Study NCT00492232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and zolpidem
Description: Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
Study NCT04111861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing
Description: To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
Study NCT02289105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory active choice
Description: the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
Study NCT00422292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL dose, intramuscular (IM)
Study NCT00422292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL dose, IM
Study NCT00422292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 Ml dose, IM
Study NCT00422292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, Rubella and Varicella
Description: 0.5 mL dose, SC
Study NCT00940641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: IV Dose
Study NCT00940641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral dose
Study NCT02833623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-message-based Re-education
Study NCT02833623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional education
Study NCT03705364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Management program
Description: Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
Study NCT00230945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and support intervention
Description: The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
Study NCT02384278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT for alcohol problems
Description: A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
Study NCT04266002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validation of Charter score for the CNS diffusion of antiretroviral drugs
Description: IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
Study NCT02114983 — intervention group
Intervention type: OTHER
Intervention: compression ultrasonography
Description: CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
Study NCT01650883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 50,000 IU PO every 10 days for 40 days
Study NCT01650883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5,000 IU
Description: Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
Study NCT01074697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant dimeglumine
Description: Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
Study NCT01074697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline water
Study NCT03420261 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: Fluid administration
Study NCT03420261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Description: Fluid administration
Study NCT02144168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotics-free enteral formula
Description: Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
Study NCT02144168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics containing enteral formula
Description: Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
Study NCT02937896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: 40 micrograms Nasal Desmopressin.
Study NCT02937896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30mg intravenous Ketorolac.
Study NCT02937896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1cc intravenous Normal Saline.
Study NCT02937896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 4 puffs nasal Normal Saline.
Study NCT01255761 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP)
Description: 400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52
Study NCT02792647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02792647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Description: Administered orally
Study NCT01313624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Study NCT01313624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Study NCT01313624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI administered via nebulizer three times daily
Study NCT02715427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Study NCT02715427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery
Study NCT00644878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
Study NCT02101268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily
Study NCT02101268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
Study NCT01438762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient information and education
Description: All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.